跳至主要内容
临床试验/NCT04497935
NCT04497935已完成不适用

Comparative, Prospective and Randomized Study of Two Preparations for the Study of the Colon Through Colonoscopy

Hospital da Senhora da Oliveira1 个研究点 分布在 1 个国家目标入组 613 人开始时间: 2019年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
613
试验地点
1
主要终点
Quality of bowel preparation between the two groups of patients

研究概览

简要总结

Compare the quality of bowel preparation between two groups of patients, who will undergo two different preparations: 1. Moviprep + diet; 2. Plenvu + diet

详细描述

The quality of bowel preparation is essential for the success of a colonoscopy, reducing colonoscopy duration, and increasing the rate of cecal intubation and of polyp detection. There are several types of preparations available on the market and, irrespective of the choice, the split-dose regimen should be followed. A reduced volume preparation makes the process easier and more tolerable, increasing adhesion. Regarding the diet to be applied before the examination, there are no advantages to a liquid diet compared to a low fiber diet, and there is no evidence on the duration of the diet. In addition, a restrictive diet has an impact on satisfaction and also on adherence to treatment.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients aged > 18 years and indicated for examination requiring bowel preparation

排除标准

  • Pregnant or breastfeeding women
  • Patients with gastroparesis or gastric obstruction.
  • Patients with psychiatric disorders
  • Severe renal impairment with CrCl <30mL/min
  • Class III-IV Heart Failure
  • Dependence / use of laxatives
  • Chronic constipation (<3 stools/week).
  • Uncontrolled hypertension (SBP >170mmHg or DBP >100mmHg)
  • Intestinal Obstruction
  • Colostomy from previous intestinal surgery
  • Severe ascites
  • Refusal of participation in the study
  • Patients unable to understand or respond to the satisfaction survey

研究组 & 干预措施

1LPEG

Patients receiving 1LPEG who had a colonoscopy in the morning were advised to follow a day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, they prepared the Dose 1 sachet in 500 mL of water and consumed it over a period of 30 minutes, followed by 500 mL of clear liquids. The second dose was then taken at 11:00 pm by mixing the two Dose 2 sachets in a single glass of 500 mL of water and consuming them over 30 minutes, followed by 500 mL of clear liquids. If the colonoscopy was scheduled for the afternoon, the same dosing instructions were given, but the first dose was taken at 7:00 am on the day of the procedure, and the second dose began at 10:00 am.

干预措施: PLENVU (Drug)

2LPEG

Patients receiving 2LPEG who had a colonoscopy in the morning were asked to follow a similar day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, the first 1L dose was consumed over a 1-hour period, followed by the second dose at 11:00 pm. For 2LPEG patients with procedures in the afternoon, they took Dose 1 at 7:00 am and Dose 2 at 10:00 am. Any patient receiving 2LPEG was also told to consume 1L of clear liquids during the preparation procedure.

干预措施: MoviPrep (Drug)

结局指标

主要结局

Quality of bowel preparation between the two groups of patients

时间窗: Patients were instructed to report any possible adverse events for up to 1 month after the procedure.

The colonoscopist assessed each of the 3 colon segments on the BBPS and assigned each a score of 0 to 3. Successful overall bowel preparation is defined as a BBPS score of \>6 with no individual segment scoring \<2.

次要结局

  • Quality of bowel preparation in patients who had a morning or afternoon colonoscopy and those who received written, oral and additional telephone re-education on the day before the colonoscopy versus written and oral information only.(Patients were instructed to report any possible adverse events for up to 1 month after the procedure.)
  • Degree of satisfaction with the two bowel preparation(Patients were instructed to report any possible adverse events for up to 1 month after the procedure.)

研究者

发起方
Hospital da Senhora da Oliveira
申办方类型
Other
责任方
Principal Investigator
主要研究者

Cátia Vanessa Meixedo Arieira

Principal Investigator

Hospital da Senhora da Oliveira

研究点 (1)

Loading locations...

相似试验